Dr. Soumya Chakravarty, MD, Ph.D., Senior Director & Strategic Lead, Rheumatology Therapeutic Area, U.S. Immunology Medical Affairs, Janssen Scientific Affairs, discusses the latest Phase 3 TREMFYA (guselkumab) data that was published in the “Annals of the Rheumatic Diseases” which demonstrated improvements in joint and skin symptoms in patients with difficult-to-treat psoriatic arthritis (PsA). The study results also show TREMFYA provided greater improvements in physical function and health-related quality of life scores compared to placebo. COSMOS is the first study to evaluate the safety and efficacy of an IL-23 inhibitor therapy in adults with active PsA and an inadequate response to tumor necrosis factor inhibition.
Soumya D. Chakravarty, MD, Ph.D. serves as Senior Director & Strategic Lead, Rheumatology Therapeutic Area, U.S. Immunology Medical Affairs, Janssen Scientific Affairs, LLC. Soumya joined Janssen in April 2016 and prior to that, was an Assistant Professor of Medicine, Division of Rheumatology at Drexel University College of Medicine and Hahnemann University Hospital, both in Philadelphia, PA. Soumya was an active clinician and clinical investigator with a focus on inflammatory arthritis disease pathogenesis and currently holds an adjunct faculty appointment there, allowing him to maintain a continuity clinic to continue treating patients.
Soumya received his B.S. in Biochemistry from the University of Michigan. He received his MD and Ph.D. from the Albert Einstein College of Medicine of Yeshiva University in NY. He completed his internal medicine residency at New York Presbyterian Hospital—Weill Cornell Medical College and fellowship/instructorship in rheumatology at Hospital for Special Surgery, both in NY. He is a Fellow of both the American College of Physicians, as well as the American College of Rheumatology. Soumya, his wife Liz, and their daughters Carolina (6yrs), Mia (3yrs), and Madeline (6mos) live in Villanova, PA. Soumya is an ardent fan of Michigan sports and enjoys classic films and travel.